KAUSAR KHAN: Open Payments
NPI 1194490359 · VERNON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,301 in 109 payments from 32 companies in 2025. Trend: 2023 $3,083 · 2024 $3,140 · 2025 $2,301
Food & beverage: $2,277Education: $24
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $294 |
| GlaxoSmithKline, LLC. | 11 | $249 |
| Lilly USA, LLC | 8 | $144 |
| Vanda Pharmaceuticals Inc. | 6 | $139 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $133 |
| Novo Nordisk Inc | 5 | $133 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $123 |
| Amgen Inc. | 5 | $101 |
| Merck Sharp & Dohme LLC | 4 | $99 |
| AstraZeneca Pharmaceuticals LP | 5 | $91 |
Products named: TRELEGY ELLIPTA, VRAYLAR, FANAPT, CAPLYTA, MOUNJARO, JARDIANCE, FREESTYLE LIBRE 3, VERQUVO.
Industry payments across CT — which companies pay providers there.
